- Home
- SKYH vs CANF Comparison
SKYH vs CANF Comparison
Compare SKYH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | CANF |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 5.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYH | CANF |
|---|---|---|
| Price | $9.69 | $0.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $13.83 | $6.75 |
| AVG Volume (30 Days) | 138.5K | ★ 19.6M |
| Earning Date | 11-12-2025 | 11-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,125,000.00 | $560,000.00 |
| Revenue This Year | $95.10 | $461.72 |
| Revenue Next Year | $71.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 95.23 | N/A |
| 52 Week Low | $8.22 | $0.28 |
| 52 Week High | $14.20 | $2.33 |
Technical Indicators
Market Signals| Indicator | SKYH | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 31.65 |
| Support Level | $9.39 | $0.31 |
| Resistance Level | $9.84 | $0.33 |
| Average True Range (ATR) | 0.37 | 0.03 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 79.46 | 0.71 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).